Travere Therapeutics, Inc.
TVTXNASDAQHealthcare● Active
$47.52
+$1.71(+3.73%)
Market Cap$4.4B
P/E Ratio—
52W High$48.61
52W Low$13.88
Travere Therapeutics, Inc.（TVTX）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · TVTX · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.49B | $0.23B | $0.15B | $0.11B | $0.13B |
| Cost of Revenue | $0.01B | $0.01B | $0.01B | $0.00B | $0.00B |
| Gross Profit | $0.48B | $0.23B | $0.13B | $0.11B | $0.13B |
| Gross Margin %(computed) | 97.89% | 96.68% | 92.12% | 95.96% | 97.10% |
| Operating Expenses | |||||
| R&D Expenses | $0.21B | $0.28B | $0.24B | $0.23B | $0.20B |
| G&A Expenses | $0.34B | $0.26B | $0.27B | $0.20B | $0.13B |
| Total Operating Expenses | $0.54B | $0.55B | $0.52B | $0.42B | $0.33B |
| Operating Income | ($0.06B) | ($0.32B) | ($0.39B) | ($0.32B) | ($0.20B) |
| Operating Margin %(computed) | -12.80% | -138.88% | -267.24% | -292.17% | -151.27% |
| Interest Income | $0.01B | $0.02B | $0.02B | $0.01B | $0.00B |
| Interest Expense | $0.01B | $0.01B | $0.01B | $0.01B | $0.02B |
| Income Before Tax | ($0.05B) | ($0.32B) | ($0.38B) | ($0.33B) | ($0.22B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.03B) | ($0.32B) | ($0.11B) | ($0.28B) | ($0.18B) |
| Net Margin %(computed) | -5.21% | -137.90% | -76.70% | -254.41% | -136.60% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.56 | $-4.08 | $-1.50 | $-4.37 | $-3.01 |
| Wtd Avg Shares | 0.09B | 0.08B | 0.07B | 0.06B | 0.06B |
| EBITDA | $0.02B | ($0.27B) | ($0.33B) | ($0.30B) | ($0.18B) |
| EBITDA Margin %(computed) | 4.53% | -113.98% | -224.63% | -273.54% | -139.91% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-08 · USD · B
深入了解Travere Therapeutics, Inc.
关于Travere Therapeutics, Inc.（TVTX）损益表
Travere Therapeutics, Inc.（TVTX）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，TVTX实现营收$0.49B，毛利润$0.48B（毛利率97.89%），净利润($0.03B)（净利率-5.21%）。
常见问题
TVTX · 4 问Travere Therapeutics, Inc.（TVTX）2025财年营收为$0.49B，同比up110.5%。
TVTX revenueTVTX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08